

BIOCON GROUP

FACT SHEET

March - 2015

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		(Rs. Crores)
	March 31, 2015	March 31, 2014
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	3,171	2,927
	3,271	3,027
Minority interest	172	82
Non-current liabilities		
(a) Long-term borrowings	770	606
(b) Deferred tax liability (net)	42	45
(c) Other long-term liabilities	552	603
(d) Long-term provisions	15	8
	1,379	1,262
Current liabilities		
(a) Short-term borrowings	261	244
(b) Trade payables	429	347
(c) Other current liabilities	706	612
(d) Short-term provisions	157	177
	1,553	1,380
TOTAL	6,375	5,751
ASSETS		
Non-current assets		
(a) Fixed assets	3,280	2,719
(b) Goodwill	26	12
(c) Non-current investments	-	65
(d) Long term loans and advances	369	269
(e) Other non-current assets	137	47
(f) Deferred tax asset	-	-
	3,812	3,112
Current assets		
(a) Current Investments	230	700
(b) Inventories	453	377
(c) Trade receivables	771	600
(d) Cash and cash equivalents	938	804
(e) Short term loans and advances	81	82
(f) Other current assets	90	76
	2,563	2,639
TOTAL	6,375	5,751

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	FY 15	FY 14	Variance
INCOME			
Biopharmaceuticals	2,236	2,138	5%
Biopharma *	1,806	1,747	3%
Branded formulations - India	430	391	10%
Contract research	823	715	15%
Total Sales	3,059	2,853	7%
Other income	84	80	4%
Total Revenue	3,143	2,933	7%
EXPENDITURE			
Material & Power costs	1,423	1,348	5%
Staff costs	493	428	15%
Research & Development **	169	131	29%
Other expenses	309	283	10%
Manufacturing, staff & other expenses	2,394	2,190	
EBITDA	749	743	1%
Interest & Finance charges	9	2	
Depreciation & Amortisation	221	203	9%
PBT BEFORE EXCEPTIONAL ITEM	519	538	-3%
Exceptional item, Net	105	-	
PBT	624	538	16%
Taxes#	96	107	
NET PROFIT BEFORE MINORITY INTEREST	528	431	23%
Minority interest	31	17	
NET PROFIT FOR THE PERIOD	497	414	20%
EPS Rs.	24.8	20.7	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	43	15	
** Gross Research & Development expenses	329	169	

Tax incidence in the hands of BRL on the sale of shares has been fully offset against business losses of BRL. BRL had created deferred tax asset of Rs 10 as at December 31, 2014 which has been utilised on consummation of sale in current quarter.

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 15	Q4 FY 14	Variance
<u>INCOME</u>			
Biopharmaceuticals	592	535	11%
Biopharma *	494	442	12%
Branded formulations - India	98	93	6%
Contract research	238	188	27%
Total Sales	830	723	15%
Other income	24	23	8%
TOTAL REVENUE	854	746	15%
<u>EXPENDITURE</u>			
Material & Power costs	376	332	13%
Staff costs	126	112	13%
Research & Development **	56	29	93%
Other expenses	94	80	17%
Manufacturing, staff & other expenses	652	553	
EBITDA	202	193	5%
Interest & Finance charges	-	1	
Depreciation & Amortisation	59	54	8%
PBT BEFORE EXCEPTIONAL ITEM	143	138	4%
Exceptional item, Net	105	-	
PBT	248	138	80%
Current taxes	22	19	
Taxes on exceptional items	10		
NET PROFIT BEFORE MINORITY INTEREST	216	119	83%
Minority interest	15	6	
NET PROFIT FOR THE PERIOD	201	113	78%
EPS Rs.	10.0	5.7	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	5	-	
** Gross Research & Development expenses	100	52	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 15	Q3 FY 15	Variance
<u>INCOME</u>			
Biopharmaceuticals	592	541	9%
Biopharma *	494	436	13%
Branded formulations - India	98	105	-6%
Contract research	238	220	9%
Total Sales	830	761	9%
Other income	24	18	34%
	854	779	10%
<u>EXPENDITURE</u>			
Material & Power costs	376	360	4%
Staff costs	126	126	0%
Research & Development **	56	47	20%
Other expenses	94	76	24%
Manufacturing, staff & other expenses	652	609	
EBITDA	202	170	19%
Interest & Finance charges	-	5	
Depreciation & Amortisation	59	56	4%
PBT BEFORE EXCEPTIONAL ITEM	143	109	32%
Exceptional item, Net	105	-	
PBT	248	109	129%
Current taxes	22	11	
Taxes on exceptional items	10		
NET PROFIT BEFORE MINORITY INTEREST	216	98	122%
Minority interest	15	7	
NET PROFIT FOR THE PERIOD	201	91	122%
EPS Rs.	10.0	5.1	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	5	10	
** Gross Research & Development expenses	100	85	